Pulmonary Embolism in a Patient With ADPKD Treated With Tolvaptan: From the Clinical Experience to the Analysis of the Food and Drug Administration Adverse Event Reporting System Registry

Ejemplares similares

• Thromboembolic Events with Cyclin-Dependent Kinase 4/6 Inhibitors in the FDA Adverse Event Reporting System
  por: Raschi, Emanuel, et al.
  Publicado: (2021)
• Development of a Network-Based Signal Detection Tool: The COVID-19 Adversome in the FDA Adverse Event Reporting System
  por: Fusaroli, Michele, et al.
  Publicado: (2021)
• Cyclin-dependent kinase 4/6 inhibitors and interstitial lung disease in the FDA adverse event reporting system: a pharmacovigilance assessment
  por: Raschi, Emanuel, et al.
  Publicado: (2020)
• The Changing Face of Drug-induced Adrenal Insufficiency in the Food and Drug Administration Adverse Event Reporting System
  por: Raschi, Emanuel, et al.
  Publicado: (2022)
• PSAT122 The Changing Face of Drug-Induced Adrenal Insufficiency in the Food and Drug Administration Adverse Event Reporting System
  por: Dalmazi, Guido D, et al.
  Publicado: (2022)